To maximise the value of their enormous real estate portfolios, pharma companies have two key strategies: continuous portfolio optimisation and capital unlocking through sale and leaseback (S&LB) transactions.
European life sciences incubators provide flexible spaces, specialised equipment, and essential support services; they also foster innovation through strong academic and industry connections, funding opportunities, and collaborative environments.